ADVISORY, Jan. 26, 2017 (GLOBE NEWSWIRE) --
What:
ObsEva SA (Nasdaq:OBSV), a biopharmaceutical company focused on the development and commercialization of novel therapeutics for
serious conditions that impact a woman’s reproductive health and pregnancy, will visit the Nasdaq MarketSite in Times Square, in
celebration of its initial public offering (IPO).
In honor of the occasion, Ernest Loumaye, Co-Founder and CEO, will ring the Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Thursday, January 26, 2017 – 9:15 a.m. to 9:30 a.m. ET
ObsEva Contact:
Liz Bryan
Spectrum Science
lbryan@spectrumscience.com
202-955-6222 x2526
Nasdaq MarketSite:
Emily Pan
(646) 441-5120
emily.pan@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please
visit our Facebook page:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/
Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market open of your choice.
About ObsEva
ObsEva is a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from
conception to birth. Between the ages of 15 and 49, millions of women worldwide suffer from reproductive health conditions that
affect their quality of life or their ability to conceive and may lead to complications during pregnancy. ObsEva aims to improve
upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and
efficacy profiles. Through strategic in-licensing and disciplined drug development, ObsEva has established a clinical-stage
pipeline with multiple development programs focused on treating the symptoms associated with uterine fibroids and endometriosis,
improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization, and treating preterm labor. For more
information, please visit www.ObsEva.com.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public
company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables clients to plan, optimize and
execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating
today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than
85 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,800 listed
companies with a market value of $10.1 trillion and approximately 18,000 corporate clients. To learn more, visit: business.nasdaq.com.
-NDAQA-
